[{"from": "human", "value": "Provide a description of this molecule. [C][O][C][C][=C][Branch2][Branch1][N][N][C][=Branch2][Ring2][=N][=C][Ring1][Branch1][C][=C][C][=Branch2][Ring2][Ring1][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][N][C][=C][Branch1][P][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][Branch1][C][F][Branch1][C][F][F][F][F][C][=Branch1][#Branch1][=N][C][=N][Ring2][Ring1][=N][N][C][N][C][C][O][C][C][Ring1][=Branch1]"}, {"from": "gpt", "value": "The molecule is an orally available, small molecule, multi-mode kinase inhibitor (MMKI), with potential antineoplastic activity. Upon oral administration, MMKI EOC317 targets, binds to and inhibits the activity of a variety of kinases, such as phosphatidylinositol 3 kinase (PI3K), and the receptor tyrosine kinases, fibroblast growth factor receptor (FGFR), angiopoietin-1 receptor (TIE 2), and vascular endothelial growth factor receptor-2 (VEGFR-2). This inhibition may result in an induction of apoptosis of susceptible tumors cells in which these kinases are overexpressed."}]